Treatment of melancholia with tranylcypromine

Abstract
Nine of 12 outpatients meeting DSM-III criteria for melancholia responded to treatment with the monoamine oxidase inhibitor (MAOI) tranylcypromine. Responders were less depressed before treatment and after treatment than were nonresponders. MAOIs appear useful in treating endogenous depressions.

This publication has 3 references indexed in Scilit: